Display options
Cite
González-Navajas JM, Elkord E, Lee J. Editorial: CD4. Front Immunol. 2021;12:737615doi: 10.3389/fimmu.2021.737615.
González-Navajas, J. M., Elkord, E., & Lee, J. (2021). Editorial: CD4. Frontiers in immunology, 12737615. https://doi.org/10.3389/fimmu.2021.737615
González-Navajas, José M, et al. "Editorial: CD4." Frontiers in immunology vol. 12 (2021): 737615. doi: https://doi.org/10.3389/fimmu.2021.737615
González-Navajas JM, Elkord E, Lee J. Editorial: CD4. Front Immunol. 2021 Sep 06;12:737615. doi: 10.3389/fimmu.2021.737615. eCollection 2021. PMID: 34552596; PMCID: PMC8450435.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2021 Sep 06;12:737615. doi: 10.3389/fimmu.2021.737615. eCollection 2021.

Editorial: CD4.

Frontiers in immunology

José M González-Navajas, Eyad Elkord, Jongdae Lee

Affiliations

  1. Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  2. Department of Pharmacology, University Miguel Hernández (UMH), Elche, Spain.
  3. School of Science, Engineering and Environment, University of Salford, Manchester, United Kingdom.
  4. School of Basic Medical Sciences and State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.

PMID: 34552596 PMCID: PMC8450435 DOI: 10.3389/fimmu.2021.737615

[No abstract available.]

Keywords: CD4; T lymphocyte; cancer; immune checkpoint inhibitor (ICI); immunotherapy

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. J Clin Invest. 2020 Dec 1;130(12):6242-6260 - PubMed
  2. Immunity. 2016 Nov 15;45(5):1135-1147 - PubMed
  3. Mol Cell Biol. 2007 Jan;27(2):518-25 - PubMed
  4. Nature. 2017 May 4;545(7652):60-65 - PubMed
  5. Semin Immunopathol. 2019 May;41(3):379-399 - PubMed
  6. Cancer Immunol Res. 2020 Mar;8(3):334-344 - PubMed

Publication Types